R. Kantor

发表

Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.

T. Silander, D. Katzenstein, Y. Moreau, 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Bayesian network analyses of resistance pathways against efavirenz and nevirapine

D. Katzenstein, R. Shafer, M. Soares, 2008, AIDS.

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy

D. Katzenstein, R. Shafer, R. Kantor, 2004, AIDS.

Optimal Allocation of Gold Standard Testing Under Constrained Availability: Application to Assessment of HIV Treatment Failure

J. Hogan, Shangxuan Zhang, R. Kantor, 2013, Journal of the American Statistical Association.

Reverse transcriptase substitution at codons 208 and 228 among treatment-experienced HIV-1 subtype-C-infected Indian patients is strongly associated with thymidine analogue mutations.

D. Katzenstein, R. Kantor, Davey M. Smith, 2012, Journal of acquired immune deficiency syndromes.

Statewide Longitudinal Trends in Transmitted HIV-1 Drug Resistance in Rhode Island, USA

Mark Howison, J. Hogan, R. Kantor, 2021, Open forum infectious diseases.

High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy

R. Kantor, S. Solomon, S. Cu-Uvin, 2018, The Journal of antimicrobial chemotherapy.

Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island.

M. Reitsma, M. Salemi, R. Kantor, 2014, Infection, Genetics and Evolution.

Risk group characteristics and viral transmission clusters in South‐East Asian patients infected with human immunodeficiency virus‐1 (HIV‐1) circulating recombinant form (CRF) 01_AE and subtype B

P. Phanuphak, R. Kantor, M. Law, 2015, The Kaohsiung journal of medical sciences.

One-Step Ligation on RNA Amplification for the Detection of Point Mutations.

R. Kantor, A. Tripathi, S. Angione, 2015, The Journal of molecular diagnostics : JMD.

The centrality of laboratory services in the HIV treatment and prevention cascade: The need for effective linkages and referrals in resource-limited settings.

R. Kantor, T. Peter, J. Nkengasong, 2014, AIDS patient care and STDs.

Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing

Emma R Lee, Mark Howison, R. Paredes, 2020, Scientific Reports.

“I just keep quiet about it and act as if everything is alright” – The cascade from trauma to disengagement among adolescents living with HIV in western Kenya

J. Fortenberry, R. Kantor, P. Braitstein, 2021, Journal of the International AIDS Society.

HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya

D. Katzenstein, J. Hogan, L. Diero, 2014, Journal of the International AIDS Society.

Beyond HIV outbreaks: protocol, rationale and implementation of a prospective study quantifying the benefit of incorporating viral sequence clustering analysis into routine public health interventions

Mark Howison, J. Hogan, R. Kantor, 2022, BMJ Open.

HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia

P. Phanuphak, R. Kantor, M. Law, 2014, Journal of the International AIDS Society.

Statistical Communications in Infectious Diseases

Mark Howison, J. Fulton, J. Hogan, 2020 .

Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome.

K. Tashima, R. Kantor, A. Delong, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Effects of political conflict-induced treatment interruptions on HIV drug resistance.

R. Kantor, S. Kimaiyo, M. Lurie, 2013, AIDS reviews.

1 Approaches for Guideline Versioning Using GLIF

M. Peleg, R. Kantor, 2003 .

Impact of HIV-1 pol diversity on drug resistance and its clinical implications

R. Kantor, 2006, Current opinion in infectious diseases.

HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.

L. Morris, R. Kantor, V. Pillay, 2008, AIDS research and human retroviruses.

Stigma Determines Antiretroviral Adherence in Adults With HIV in Myanmar

R. Kantor, A. Rana, S. Chrysanthopoulou, 2021, Journal of acquired immune deficiency syndromes.

Inference for BART with Multinomial Outcomes

M. Daniels, J. Hogan, R. Kantor, 2021, ArXiv.

Tree-based Subgroup Discovery In Electronic Health Records: Heterogeneity of Treatment Effects for DTG-containing Therapies

J. Hogan, R. Kantor, I. Dahabreh, 2022, 2208.14329.

Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance

R. Kantor, C. Boucher, C. Godfrey, 2017, The Journal of infectious diseases.

“I have never talked to anyone to free my mind” – challenges surrounding status disclosure to adolescents contribute to their disengagement from HIV care: a qualitative study in western Kenya

J. Fortenberry, R. Kantor, W. Nyandiko, 2022, BMC Public Health.

Challenges in evaluating the use of viral sequence data to identify HIV transmission networks for public health

Mark Howison, J. Fulton, J. Hogan, 2020, Statistical communications in infectious diseases.

Bioinformatic data processing pipelines in support of next‐generation sequencing‐based HIV drug resistance testing: the Winnipeg Consensus

Emma R Lee, Mark Howison, R. Paredes, 2018, Journal of the International AIDS Society.

Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

D. Katzenstein, R. Kantor, K. Mayer, 2009, Journal of virological methods.

The centrality of laboratory services in the HIV treatment and prevention cascade: The need for effective linkages and referrals in resource-limited settings.

R. Kantor, T. Peter, J. Nkengasong, 2014, AIDS patient care and STDs.

SARS‐CoV‐2 and HIV coinfection: clinical experience from Rhode Island, United States

K. Tashima, R. Kantor, C. Beckwith, 2020, Journal of the International AIDS Society.

Current Status of Point‐of‐Care Testing for Human Immunodeficiency Virus Drug Resistance

Iain J. MacLeod, James J. Lai, Ingrid A. Beck, 2017, The Journal of infectious diseases.

Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes

D. Katzenstein, J. Hogan, S. Istrail, 2015, Open forum infectious diseases.

HIV-2 diagnosis and quantification in high-risk patients

S. Wakeman, R. Kantor, T. Flanigan, 2008, AIDS research and therapy.

Online Hookup Sites for Meeting Sexual Partners among Men Who Have Sex with Men in Rhode Island, 2013: A Call for Public Health Action

R. Kantor, J. Rose, P. Chan, 2016, Public health reports.

Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA

Pardis C Sabeti, Mark Howison, R. Tewhey, 2022, Cell Reports Medicine.

Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations

Hezhao Ji, Rami Kantor, Santiago Ávila-Ríos, 2020, Viruses.

Human immunodeficiency virus reverse transcriptase and protease sequence database.

Bradley J. Betts, Matthew J. Gonzales, Soo-Yon Rhee, 2003, Nucleic acids research.

Transmitted drug resistance in nonsubtype B HIV-1 infection.

R. Kantor, P. Chan, 2009, HIV therapy.

Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.

D. Katzenstein, R. Kantor, 2003, AIDS reviews.

Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs

Matthew J. Gonzales, Robert W. Shafer, Rami Kantor, 2001, Nucleic Acids Res..

Global epidemiology of drug resistance after failure of WHO recommended fi rst-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Huldrych F. Günthard, Tulio de Oliveira, Lynn Morris, 2019 .

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2005, PLoS medicine.

Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors

Thomas D. Wu, R. Shafer, A. Zolopa, 2003, AIDS.

The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Rami Kantor, Robert W Shafer, Matthew J Gonzales, 2000, AIDS reviews.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation

Philip L. Tzou, D. Katzenstein, R. Shafer, 2017, PloS one.

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration

Huldrych F. Günthard, Dominique Goedhals, Susan P. Holmes, 2017, EBioMedicine.

HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1–Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077

D. Katzenstein, R. D’Aquila, R. Bosch, 2014, PloS one.

HIV-1 Treatment Failure, Drug Resistance, and Clinical Outcomes in Perinatally Infected Children and Adolescents Failing First-Line Antiretroviral Therapy in Western Kenya

J. Hogan, S. Ayaya, R. Kantor, 2021, Journal of acquired immune deficiency syndromes.

Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

J. Hogan, L. Diero, R. Kantor, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.

R. Schooley, R. Kantor, K. Mayer, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.

D. Katzenstein, M. Winters, R. Kantor, 2007, AIDS research and human retroviruses.

Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.

D. Katzenstein, C. Contag, L. Mofenson, 2005, The Journal of infectious diseases.

Classification using ensemble learning under weighted misclassification loss

Tao Liu, Michael J. Daniels, Joseph W. Hogan, 2018, Statistics in medicine.

SARS-CoV-2 Variants in Rhode Island.

Mark Howison, R. Kantor, A. Tripathi, 2021, Rhode Island medical journal.

SARS-CoV-2 Variants in Rhode Island; May 2022 Update.

Mark Howison, R. Kantor, R. Huard, 2022, Rhode Island medical journal.

Detection of HIV-1 minority variants containing the K103N drug-resistance mutation using a simple method to amplify RNA targets (SMART).

R. Kantor, A. Tripathi, K. Morabito, 2013, The Journal of molecular diagnostics : JMD.

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa

D. Katzenstein, R. Kantor, A. Sohn, 2013, Journal of the International AIDS Society.

Transmission Networks of HIV-1 Among Men Who Have Sex With Men in East and Southeast Asia.

P. Phanuphak, R. Kantor, Y. Takebe, 2015, Journal of acquired immune deficiency syndromes.

Potential COVID-19 Endgame Scenarios: Eradication, Elimination, Cohabitation, or Conflagration?

E. Adashi, R. Kantor, Aaron D. Kofman, 2021, JAMA.

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

Anne-Mieke Vandamme, Soo-Yon Rhee, Tommy F. Liu, 2009, PloS one.

Envelope Coreceptor Tropism, Drug Resistance, and Viral Evolution Among Subtype C HIV-1-Infected Individuals Receiving Nonsuppressive Antiretroviral Therapy

D. Katzenstein, R. Kantor, S. Kassaye, 2009, Journal of acquired immune deficiency syndromes.

Next Generation Sequencing for HIV-1 Drug Resistance Testing—A Special Issue Walkthrough

R. Kantor, 2021, Viruses.

Added Value of Next Generation over Sanger Sequencing in Kenyan Youth with Extensive HIV-1 Drug Resistance

M. Scanlon, J. Hogan, R. Kantor, 2022, Microbiology spectrum.

Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping

Emma R Lee, Mark Howison, Shuntai Zhou, 2020, Viruses.

External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations

N. Parkin, R. Kantor, T. Denny, 2020, Viruses.

Measurement error and variant-calling in deep Illumina sequencing of HIV

Mark Howison, Rami Kantor, Mia Coetzer, 2018, bioRxiv.

Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase.

J. Hogan, Zhijin Wu, N. Parkin, 2012, AIDS research and human retroviruses.

Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India.

R. Schooley, R. Kantor, Davey M. Smith, 2013, AIDS research and human retroviruses.

Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.

R. Kantor, E. Nerrienet, J. Harwell, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study

R. Shafer, P. Kaleebu, D. Pillay, 2016, The Lancet. Infectious diseases.

Antiretroviral treatment failure, drug resistance, and subtype diversity in the only pediatric HIV clinic in Rhode Island.

R. Kantor, P. Chan, A. Delong, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

T. F. Rinke de Wit, D. Katzenstein, R. Shafer, 2015, PloS one.

Real-Life Feasibility of HIV Drug Resistance Testing Using Dried Filter Analytes in Kenyan Children and Adolescents Living with HIV

J. Hogan, R. Kantor, W. Nyandiko, 2022, Microbiology spectrum.

Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV

R. Kantor, T. Puthanakit, W. Nyandiko, 2021, Journal of the International AIDS Society.

Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non-Subtype B HIV-1–Infected Patients in South East Asia

S. Sirivichayakul, P. Phanuphak, R. Kantor, 2014, Journal of acquired immune deficiency syndromes.

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

M. Reitsma, J. Mellors, R. Kantor, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing

Hezhao Ji, Rami Kantor, Emma R Lee, 2020, Viruses.

Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences

Sergei L. Kosakovsky Pond, Philip L. Tzou, R. Shafer, 2019, bioRxiv.

HIV Drug Resistance and Transmission Networks Among a Justice-Involved Population at the Time of Community Reentry in Washington, D.C.

Mark Howison, R. Kantor, C. Beckwith, 2021, AIDS research and human retroviruses.

Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium

R. Paredes, P. Harrigan, N. Parkin, 2020, Viruses.

Evaluation of peer-to-peer HIV counseling in Myanmar: a measure of knowledge, adherence, and barriers

R. Kantor, A. Rana, S. Chrysanthopoulou, 2021, AIDS care.

Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines.

R. Kantor, M. Coetzer, E. Nerrienet, 2013, AIDS research and human retroviruses.

Characterization of HIV-Related Stigma in Myanmar

R. Kantor, A. Delong, Su N Aung, 2023, AIDS and Behavior.

HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya

M. Reitsma, J. Hogan, L. Diero, 2018, AIDS.

Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.

D. Katzenstein, Z. El-Khatib, M. Petzold, 2011, Journal of AIDS & clinical research.

Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya

Maya Balamane, Joseph Hogan, Rami Kantor, 2016, Journal of the International AIDS Society.

Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India

D. Katzenstein, R. Kantor, K. Mayer, 2009, Antiviral therapy.

Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

D. Katzenstein, R. Kantor, K. Mayer, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance in non-subtype B HIV-1.

Rami Kantor, David Katzenstein, D. Katzenstein, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Social, economic, and health effects of the COVID-19 pandemic on adolescents retained in or recently disengaged from HIV care in Kenya

R. Kantor, K. Wools-Kaloustian, A. Gardner, 2021, PloS one.

A Challenging Knowledge Gap: Estimating Modes of HIV Acquisition Among Adolescents Entering HIV Care During Adolescence

R. Kantor, W. Nyandiko, K. Wools-Kaloustian, 2022, Global pediatric health.

The HIV epidemic among adolescents living with HIV (AHIV; 10-19 years of age) in sub-Saharan Africa is uniquely driven by perinatal and non-perinatal modes

R. Kantor, W. Nyandiko, K. Wools-Kaloustian, 2022 .

HemaSpot, a Novel Blood Storage Device for HIV-1 Drug Resistance Testing

L. Diero, R. Kantor, P. Chan, 2015, Journal of Clinical Microbiology.

TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.

D. Katzenstein, R. Kantor, S. Oka, 2009, Journal of virological methods.

Transmitted Drug Resistance and Molecular Epidemiology in Antiretroviral Naive HIV Type 1-Infected Patients in Rhode Island

K. Tashima, R. Kantor, P. Chan, 2011 .

High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment

Rami Kantor, D. Katzenstein, R. Kantor, 2003, Journal of Virology.

Global analysis of sequence diversity within HIV-1 subtypes across geographic regions.

D. Katzenstein, J. Hogan, S. Istrail, 2012, Future virology.

The association between HIV-1 subtype C antiretroviral resistance and HLA prevalence in southern India.

R. Kantor, Davey M. Smith, K. Mayer, 2011, Journal of acquired immune deficiency syndromes.

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments

Thomas D. Wu, R. Shafer, C. Schiffer, 2003, Journal of Virology.

Journal of the International Aids Society the Hiv-1 Non-subtype B Workgroup: an International Collaboration for the Collection and Analysis of Hiv-1 Non-subtype B Data Hiv Diversity and Drug Resistance the Global Paradox

D. Katzenstein, R. Shafer, R. Kantor, 2022 .

The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data.

D. Katzenstein, R. Shafer, R. Kantor, 2005, MedGenMed : Medscape general medicine.

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis

R. Kantor, Austin Huang, P. Chan, 2012, Journal of the International AIDS Society.

Phylogenetic Investigation of a Statewide HIV-1 Epidemic Reveals Ongoing and Active Transmission Networks Among Men Who Have Sex With Men

J. Hogan, M. Salemi, R. Kantor, 2015, Journal of acquired immune deficiency syndromes.

Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2006, Antimicrobial Agents and Chemotherapy.

HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.

D. Katzenstein, R. Shafer, R. Kantor, 2002, AIDS research and human retroviruses.

HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes

Lynn Morris, Soo-Yon Rhee, Rami Kantor, 2006, AIDS.

HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India.

D. Katzenstein, R. Kantor, K. Mayer, 2005, AIDS research and human retroviruses.

Not all clusters are equal: dynamics of molecular HIV-1 clusters in a statewide Rhode Island epidemic

Mark Howison, J. Hogan, R. Kantor, 2022, AIDS.

Transmitted HIV drug resistance at the Thai Red Cross anonymous clinic in Bangkok: results from three consecutive years of annual surveillance.

K. Ruxrungtham, S. Sirivichayakul, P. Phanuphak, 2014, The Journal of antimicrobial chemotherapy.

“Who am I going to stay with? Who will accept me?”: family‐level domains influencing HIV care engagement among disengaged adolescents in Kenya

R. Kantor, P. Braitstein, W. Nyandiko, 2022, Journal of the International AIDS Society.

Statewide Evaluation of New HIV Diagnoses in Rhode Island: Implications for Prevention

R. Kantor, K. Mayer, J. Rose, 2018, Public health reports.

Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

R. Schooley, R. Kantor, Davey M. Smith, 2012, AIDS research and human retroviruses.

Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy

Robert W. Shafer, Rami Kantor, Jonathan M. Schapiro, 2002, Antimicrobial Agents and Chemotherapy.

DirectDetect SARS-CoV-2 Direct Real-Time RT-PCR Study Using Patient Samples

R. Kantor, C. Beckwith, A. Tripathi, 2022, ACS omega.

Interrupting transmission of HIV and other sexually transmitted infections in Rhode Island.

R. Kantor, P. Simon, P. Chan, 2012, Medicine and health, Rhode Island.

Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions

Soriano, D. Katzenstein, R. Shafer, 2003 .

Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load.

R. D’Aquila, R. Kantor, S. Cu-Uvin, 2013, Journal of women's health.

Incorporating Within-Host Diversity in Phylogenetic Analyses for Detecting Clusters of New HIV Diagnoses

Mark Howison, R. Kantor, C. Dunn, 2022, Frontiers in Microbiology.

Empirical comparison of analytical approaches for identifying molecular HIV-1 clusters

Mark Howison, Casey W. Dunn, Vlad Novitsky, 2020, Scientific Reports.

R. Kantor, W. Nyandiko, R. Vreeman, 2023, Journal of the International Association of Providers of AIDS Care.

Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.

R. Kantor, Davey M. Smith, S. Mothi, 2016, AIDS research and human retroviruses.

Comparison of machine learning methods for predicting viral failure: a case study using electronic health record data

Joseph W. Hogan, Rami Kantor, Jonathan Dick, 2020, Statistical communications in infectious diseases.

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors are subtype dependent

Lynn Morris, Anne-Mieke Vandamme, Praphan Phanuphak, 2004 .

Short communication: new HIV infections at Southern New England academic institutions: implications for prevention.

R. Kantor, T. Flanigan, K. Mayer, 2013, AIDS research and human retroviruses.

Prescription for life: take action to help children living with HIV.

Pillay, A. Dia, R. Kantor, 2008 .

Antiretroviral Treatment Interruptions Induced by the Kenyan Postelection Crisis Are Associated With Virological Failure

Rami Kantor, Leeann Schreier, Lameck Diero, 2013, Journal of acquired immune deficiency syndromes.

Comparison of predicted susceptibility between genotype and virtual phenotype HIV drug resistance interpretation systems among treatment-naive HIV-infected patients in Asia: TASER-M cohort analysis

S. Sirivichayakul, R. Kantor, Patrick C. K. Li, 2012, BMC Research Notes.

K103N mutation in antiretroviral therapy-naive African patients infected with HIV type 1.

R. Kantor, K. Henry, Charles Cartwright, 2004, Clinical Infectious Diseases.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

Domenico Di Carlo, P. A. Bester, R. Shafer, 2022 .

Approaches for Guideline Versioning Using GLIF

Mor Peleg, Rami Kantor, M. Peleg, 2003, AMIA.

Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV.

R. Kantor, C. Beckwith, L. Bazerman, 2021, Journal of correctional health care : the official journal of the National Commission on Correctional Health Care.

Added Value of Next Generation Sequencing in Characterizing the Evolution of HIV-1 Drug Resistance in Kenyan Youth

Mark Howison, J. Hogan, R. Kantor, 2023, Viruses.

QColors: An algorithm for conservative viral quasispecies reconstruction from short and non-contiguous next generation sequencing reads

Sorin Istrail, Rami Kantor, Austin Huang, 2011, 2011 IEEE International Conference on Bioinformatics and Biomedicine Workshops (BIBMW).

Improved HIV-1 Viral Load Monitoring Capacity Using Pooled Testing With Marker-Assisted Deconvolution

Michael J. Daniels, Joseph W. Hogan, Yizhen Xu, 2017, Journal of acquired immune deficiency syndromes.

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

M. Reitsma, J. Mellors, R. Kantor, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Ethical Considerations for Engaging Youth Living with HIV in Research: Perspectives from Youth, Their Caregivers and Subject Matter Experts in Kenya

R. Kantor, W. Nyandiko, R. Vreeman, 2023, Journal of empirical research on human research ethics : JERHRE.

Classification using ensemble learning under weighted misclassification loss

M. Daniels, J. Hogan, R. Kantor, 2018, Statistics in medicine.

We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy.

R. Kantor, Ravindra K. Gupta, 2023, The lancet. HIV.

Rilpivirine resistance-associated mutations among antiretroviral-naive patients infected with HIV-1 in Asia.

S. Sirivichayakul, R. Kantor, S. Kiertiburanakul, 2013, Journal of acquired immune deficiency syndromes.

An Automated Bioinformatics Pipeline Informing Near-Real-Time Public Health Responses to New HIV Diagnoses in a Statewide HIV Epidemic

J. Hogan, R. Kantor, C. Dunn, 2023, Viruses.

Gp41 and Gag amino acids linked to HIV‐1 protease inhibitor‐based second‐line failure in HIV‐1 subtype A from Western Kenya

L. Diero, R. Kantor, M. Coetzer, 2017, Journal of the International AIDS Society.

Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

D. Katzenstein, R. Kantor, K. Mayer, 2009, Journal of virological methods.

Research components of the Brown Kenya Program: a personal and professional perspective.

Rami Kantor, R. Kantor, 2013, Rhode Island medical journal.

Longitudinal typing of molecular HIV clusters in a statewide epidemic

J. Fulton, J. Hogan, R. Kantor, 2021, AIDS.